Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the
inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was
investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19
beyond available treatments. Methods In LIVE-AIR, a phase 3, randomised, double-blind …
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the
inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was
investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19
beyond available treatments. Methods In LIVE-AIR, a phase 3, randomised, double-blind …
以上显示的是最相近的搜索结果。 查看全部搜索结果